Conduzido em 13 Apr 2022 05:48 am
Dr. Shaheenah Dawood
Overview of following important abstracts from SABCS 2021 :
- DESTINY-Breast03 study subgroup analysis: comparing deruxtecan (T-DXd) over T-DM1 in patients with HER2-positive breast cancer and brain metastases
- SUMMIT study: of neratinib for patients with HER2 mutations
- SOFT and TEXT clinical trials: 12-year follow-up results
- Meta-analysis of 7,030 patients: aromatase inhibitors versus tamoxifen in pre-menopausal patients with ER-positive early-stage breast cancer treated with ovarian suppression
- PADA 1 clinical trial: evaluating early switch to Fulvestrant/Palbociclib based on ESR1 mutation vs continuing aromatase inhibitor-based treatment
